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FACTORS ASSOCIATED WITH INITIATION OF HIGH-DOSE DULOXETINE AMONG
PATIENTS WITH OSTEOARTHRITIS
Peng X1, Wu N2, Andrews JS1, Chen SY2, Boulanger L2
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2United BioSource Corporation, Lexington,
MA, USA
OBJECTIVES: To identify pre-treatment predictors associated with high initiating
doses of duloxetine therapy for patients with osteoarthritis (OA). METHODS: Pa-
tients with OA diagnosis who initiated duloxetine between November 1, 2010 to
March 31, 2011 were selected from a medical and pharmacy claims database. The
dispense date of the first duloxetine prescription preceded by at least a 90-day gap
in medication supply was defined as the index date. Comorbidities and prior med-
ication use were assessed during six months prior to the index date. Multiple
logistic regression models were performed to identify predictors of initiating du-
loxetine: 1) 60mg versus 60mg, and 2) 60mg versus 60mg. RESULTS: A total of
2034OApatients (mean age 63.7 years; 75.5% female)who initiated duloxetinewere
identified. Common comorbidities included hypertension (57.4%), depression
(35.3%) and diabetes (29.4%). Common pain medications used prior to duloxetine
initiation were opioids (71.5%, 69.4% and 16.5% on short- and long-acting opioids,
respectively), antidepressants (52.4%), and non-steroidal anti-inflammatory drug
(NSAIDs, 36.5%). Of the duloxetine initiators, 50.3% started on 60mg, 38.7% 60mg
and 10.9% 60mg. Compared to patients 18-44 years old, patients 75 years old
were more likely to start on a dose60mg (Odds Ratio [OR]: 1.89, 95% Confidence
Interval [CI]: 1.19-3.01). Patients with prior use of opioid (OR: 0.75, 95% CI: 0.60-0.94)
or hypertension (OR: 0.74, 95% CI: 0.60-0.92) were less likely to start on 60mg,
whereas patients with prior use of NSAIDs (OR: 1.24, 95% CI: 1.01-1.53) or malig-
nancy (OR: 1.53, 95%CI: 1.06-2.21) weremore likely to start on60mg. Patientswith
prior use of duloxetine (OR: 1.67, 95% CI: 1.08-2.57) or depression (OR: 1.61, 95% CI:
1.12-2.31) were more likely to start on a dose60mg. CONCLUSIONS: Most of the
patients initiated duloxetine at 60mg/day. Presence of selected comorbidities and
prior use of medications were associated with higher starting dose of duloxetine
among OA patients.
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ADHERENCE AND URIC ACID GOAL ATTAINMENT WITH URATE LOWERING
THERAPY IN PATIENTS WITH GOUT
Rashid N1, Cheetham CT2, Niu F1
1Kaiser Permanente Southern California, Downey, CA, USA, 2Kaiser Permanente, Downey, CA,
USA
OBJECTIVES: Evaluate patient and prescriber characteristics associated with gout
patients newly initiating allopurinol; evaluate adherence within this population.
METHODS: Retrospective study of gout patients was conducted using Kaiser Per-
manente Southern California health care data. Patients aged 18 years and older
with a diagnosis of gout (ICD9 274.xx) and allopurinol prescription from January 1,
2007 to June 31, 2010 were included. Incident allopurinol users were defined as
patients that had no allopurinol prescription within 12months prior of the 1st gout
diagnosis (index date). Patients had at least 12 months of follow up after their 1st
allopurinol prescription. Descriptive statistics such as age, gender, race, co-morbid
conditions, concomitant medications, prescriber specialty, and allopurinol dose
adjustment were calculated comparing patients at sUA goal (6mg/dl) or not at
sUA goal. MPR mean and adherence was measured using the medication posses-
sion ratio (MPR) over the followup time period andwas defined as 80%. RESULTS:
A total of 9288 gout patientswere identified as incident allopurinol users (mean age
60 years, men 78%). All patients had at least one comorbid condition with the
following conditions being the most common: hypertension (73%), chronic kidney
disease (32%), and diabetes (25%). Hydrochlorothiazide (21%) and furosemide (17%)
were the most commonly utilized concomitant medications. At the end of obser-
vation, 2,749 patients (30%) were at sUA goal (mean age 63 years, men 71%) versus
6539 patients not at goal (mean age 59 years, men 81%). ThemeanMPR for patients
at goal was 92% versus 77% for patients not at goal. A total of 1793 patients (65%)
were adherent and at goal versus 40% were adherent but not at goal.
CONCLUSIONS: Sixty percent of incident allopurinol users do not have UA goal
attainment and are less adherent. Efforts need to bemade to improve adherence to
better obtain goal attainment.
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DERIVATION OF SEVERITY INDEX FOR RHEUMATOID ARTHRITIS AND ITS
EFFECT ON HEALTH CARE OUTCOMES
Baser O1, Wang L2, Xie L1, Du J3, Wang H4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA, 4The University of Michigan, Ann
Arbor, MI, USA
OBJECTIVES: To develop a claims-based severity index for rheumatoid arthritis
(RA) using large US claims data. METHODS: Adult patients with at least two RA
diagnoses 2 months apart were identified from a large US claims database (10/1/
2008-09/30/2009). Patients were required to have at least 12 months continuous
health plan enrollment before and after the index date (first RA diagnosis date). A
severity index for rheumatoid arthritis (SIFRA) was developed by calculating a
weighted sum of 47 RA-related indicators including laboratory, clinical and func-
tional status, extra-articular manifestations, surgical history, and medications as-
sessed by an expert Delphi panel of six rheumatologists. Two versions of SIFRA
were derived for patients with and without laboratory information. Correlations
between SIFRA and previously validated claims-based indexes for RA severity (CI-
RAS), and other traditional comorbidity indexes were calculated. The relationship
between SIFRA and heath care costs was also examined using histograms.
RESULTS: The Spearman’s rank correlations between SIFRA and CIRAS were 0.525
for SIFRA without laboratory data and 0.539 for SIFRA with laboratory data. The
correlations between SIFRA and the Charlson Comorbidity Index (0.1503 without,
0.1135 with laboratory data), Elixhauser Index (0.105 without, 0.079 with laboratory
data) and Chronic Disease Score (CDS) (0.255 without, 0.239 with laboratory data)
were low. Histograms showed that patients in the upper tercile of SIFRA incurred
$9,123 more all-cause health care costs and $1,326 more RA-related health care
costs than patients in the lower tercile of SIFRA. CONCLUSIONS: SIFRA was found
to havemoderate correlationswith the previously validated CIRAS score, and dem-
onstrated evidence of being a significant determinant of total and RA-related
health care costs for RA patients. This study suggests that SIFRA could be an im-
portant methodological tool to control for severity in RA-related outcomes re-
search.
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WHY THE FINDINGS OF PUBLISHED RHEUMATOID ARTHRITIS MULTIPLE
TREATMENT COMPARISONS ARE SO DIFFERENT - AN OVERVIEW OF
RECURRENT METHODOLOGICAL SHORTCOMINGS
Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES: To methodologically review the published literature on rheumatoid
arthritis multiple treatment comparison meta-analysis (MTCs). To identify meth-
odological issues that can explain the substantial discrepancies in the findings of
these MTCs. METHODS: We searched MEDLINE for rheumatoid arthritis multiple
treatment comparisons. Following the PRISMA guidelines, we extracted a large set
of methodological items from the identified reviews. These included, but were not
limited to, inclusion/exclusion criteria, information sources (e.g., MEDLINE), ap-
proaches to dealing with monotherapies versus combination therapies, ap-
proaches to dealing with potential covariate effect modifiers (i.e., sources of
heterogeneity). RESULTS: We identified 11 published MTC, of which 7 were pub-
lished since 2009. We identified major discrepancies in the inclusion of trials, de-
spite highly similar eligibility criteria and literature searches. The total number of
trials covered among all MTCs was 61. The number of trials, however, included in
the individual MTCs published since 2009 spanned from 15 to 31 – i.e., 25%-50% of
all available trials. We identified inconsistencies in approaches to dealing with
monotherapy and combination therapy trials. Most MTCs lumped the two sets of
trials without either controlling for the effect of concomitant use of disease mod-
ifying anti rheumatic drugs (DMARDs) or separately comparing the effectiveness
estimates in the two. Approximately half of the identified MTCs did not explore
potential sources of heterogeneity. Among those that did, the explored sources
were inconsistent.CONCLUSIONS:Majormethodological shortcomings and incon-
sistencies exist throughout published rheumatoid arthritis MTCs. There are many
lessons to be learned from these previous publications which can potentially
strengthen the current evidence base.
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USE OF COMMON DATA MODEL TO ENABLE MEANINGFUL COMPARISON OF
DISEASE BURDEN AMONG DISPARATE DATABASES
Schneider G1, Powell G2, Reisinger S3
1United BioSource Corporation, Lexington, MA, USA, 2GlaxoSmithKline, RTP, NC, USA, 3United
BioSource Corporation, Harrisburg, PA, USA
OBJECTIVES: Use of a Common Data Model (CDM) to standardize underlying data
assumptions and format enables consistency in the application of research meth-
ods and production of meaningfully comparable results across disparate data
sources. This study compared the baseline disease burden, as measured via a
standardmethod deriving Charlson Comorbidity Index (CCI), which was applied to
multiple observational databases after all source datawas transformed into a stan-
dard CDM format.METHODS: Two unique patient cohorts, 1) newly diagnosed and
treated depression patients (DEP), and 2) newly diagnosed rheumatoid arthritis
patients (RA) were identified using equivalent definitions from multiple claims
databases which had been previously transformed into a standard CDM format.
CCI was calculated for each Cohort using a single SAS macro developed for CCI
derivation using CDM-format data Descriptive information on CCI, in aggregate
and stratified by age category and gender,was compared separately for theDEP and
RA cohorts across all databases. RESULTS: Despite a common data format, consis-
tent cohort definitions, and a single method for CCI derivation, the calculated CCI
varied by asmuch as 20% (RA) and 50% (DEP) across the different databases used for
this study. Gender had little influence on CCI differential. CCI differential generally
decreased with advancing age category for both DEP and RA, with largest differen-
tials exceeding 4-fold in 18-30 age group (DEP) and smallest differentials of 10% in
80 age group (DEP). CONCLUSIONS: Common Data Models provide an efficient
way of enabling meaningful comparisons across disparate data sources. Dispari-
ties in CCI results, despite identical cohort definitions and the application of a
single SAS macro, are likely the result of differences in underlying populations,
data capture process, and/or functional ability and/or incentive to record complete
information in source data. Future research should focus on how each of these
factors may impact disease burden indices.
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OSTEOARTHRITIS IN FRANCE THE COST OF AMBULATORY CARE IN 2010
Taieb C
CREES PFSA, Boulogne, France
OBJECTIVES: In France, the cost of an osteoarthritic patient has not been estimated
for several years.The aim of the study was to evaluate the annual cost of the
treatment given to osteoarthritic patients by GP.METHODS: The cohort was made
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up of patients who were diagnosed with osteoarthritis between April 2009 and
March 2010 (IMS Disease Analyzer database) The cost includes all medical cost to
the patients in the cohort, and colligated in the Disease Analyzer database (all
consultations with GPs and all resulting drug prescriptions). The evaluated cost is
therefore the annual cost of treatment given to an osteoarthritic patient. RESULTS:
A total of 18,976 patients suffering from osteoarthritis were followed. For these
patients, who had an average age of 66, all consultations with GPs as well as all
resulting drug prescriptions were valued both in terms of societal cost and cost to
health insurance. The average annual cost of disease management by a GP of a
patient suffering from osteoarthritis is therefore valued at €755 societal cost, of
which around 60% (€447) is paid by health insurance. The annual cost of treatment
by a GP of a patient suffering from hip osteoarthritis is significantly lower at the
societal level (€715) than at the health insurance level (€425) compared to patients
suffering from osteoarthritis in the knee or elsewhere, despite their higher age.
CONCLUSIONS: No literary data evaluating the cost of an osteoarthritic patient
currently exists. The closest data is that produced by a COART® France study (Le
Pen and coll, Revue du rhumatisme, December 2005). The prevalence of osteoar-
thritis has been estimated at around 4 million sufferers, even though this figure
may be conservative, we can estimate that the cost of osteoarthritis treatment is
around 3 billion euros. We are sure that further data will be added to existing ones.
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MIXED TREATMENT COMPARISON, COST-EFFECTIVENESS ANALYSIS AND
BUDGET IMPACT MODEL IN THE TREATMENT OF RHEUMATOID ARTHRITIS
AFTER FAILURE OF CONVENTIONAL DMARD THERAPY USING COMPREHENSIVE
BAYESIAN DECISION ANALYTICAL MODELLING
Launois R, Le Moine JG, Huynh TMT
Rees France, Paris, France
OBJECTIVES: Eighteen percent of patients with rheumatoid arthritis (RA) escape
conventional treatment with Methotrexate and hence biological agents like TNF-
inhibitors are also used. Given a population of patients with severe rheumatoid
arthritis we sort to assess efficacy and safety after failure of DMARD, to estimate
the budget impact of the management of RA in France, to compare between aver-
age annual cost of maintaining a patient under treatment and finally to evaluate
the cost-effectiveness of different available strategies.METHODS:We carried out a
systematic review of randomized control trials conducted between 1999 and 2010
on patients with RA on treatment with one of the biological agents, a quantitative
synthesis of the evidence from random effects mixed treatment comparison was
also done and a Markov model to assess budget impact and cost effectiveness of
different strategies was constructed. We assumed that (i) Response, discontinua-
tion and infection rates where constant over time (ii) model results in terms of cost
and effectiveness were calculated considering 1st line, 2nd line and both (iii) Evolu-
tional trends in market shares for the most effective drug where analyzed. Sensi-
tivity analysis was also performed RESULTS: Biotherapy differed significantly from
DMARDs in terms of ACR 50 response. Given a willingness to pay of 1,715€ Adali-
mumab was efficient, beyond this WTP threshold, Etanercept was the most effec-
tive treatment. A comparison of an increase or decrease in Etanerceptmarket share
shows that the replacement of ETA by more expensive and or/less effective thera-
pies results in a loss estimated at 28million euros over 5years.Considering only 1st
or 2nd line of biotherapy, results in a 4.04% increase of average annual cost of
managing a patient after failure of DMARDs CONCLUSIONS: Substitution of more
expensive biological therapieswithout additional therapeutic benefit to the patient
implies economic loss for society.
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SIMULATION MODELING WITH SYSTEM DYNAMICS (SD) USING REAL-WORLD
OBSERVATIONAL DATA TO PLAN OSTEOARTHRITIS CARE DELIVERY IN
ALBERTA
Marshall D1, Vanderby S2, Enns E3, Frank C3, Wasylak T4, Mosher DP1, Noseworthy T1,
Rogers P1, Maxwell C1, Sundaram A3, Carter M5
1University of Calgary, Calgary, AB, Canada, 2University of Saskatchewan, Saskatoon, SK,
Canada, 3Alberta Bone & Joint Health Institute, Calgary, AB, Canada, 4Alberta Health Services,
Calgary, AB, Canada, 5University of Toronto, Toronto, ON, Canada
OBJECTIVES: Currently, there are no reliable and validated methods for health
service decision-makers to inform policy on quality care at a systems level. To
address this need, we worked with health administrators, clinicians and research-
ers to create and validate a decision-support tool that service planners can use to
achieve a sustainable, integrated care system for hip and knee OA.METHODS: The
SDmodel reflects the continuumof care, including self-directed, primary, rheuma-
tologic and orthopaedic specialist for hip and knee replacement, acute, rehabilita-
tion, community and surgical follow-up care. The model was developed in four
phases, with phase 1 focusing on demand and flow rates, phase 2 on resources,
phase 3 adding geographical stratification, and phase 4 adding feedback loops. We
populated the model with administrative data from Alberta Health & Wellness
(physician claims, inpatient, and ambulatory data), Survey of Living with Chronic
Diseases in Canada, and clinical/surgical data from Alberta Bone and Joint Health
Institute. Using established principles of SD modeling and an iterative process of
integrated knowledge translation we defined the problem, modeled the system as
a series of stock and flows, and validated themodel. Throughmultiple workshops,
experts from front-line clinical staff and administrators provided input and im-
proved face validity. RESULTS: OA care process diagrams were the preferred for-
mat for developing the model structure. The fully specified SD model has been
validated with end-users and can be used as a decision-support tool to test scenar-
ios and their resulting effects on system performance and costs. CONCLUSIONS:
Based on multiple real-world observational data sources, this SD Model allows
evaluation of alternative clinical and administrative scenarios that reflect antici-
pated changes in health care demands and service. Furthermore, the integrated
knowledge translation process reflects the critical importance of involving clini-
cians and decision-makers when developing a system dynamicsmodel for applied
use.
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THE INFLUENCE OF ‘WEAK LINKS’ ON COMPARATIVE TREATMENT EFFECTS IN
MULTIPLE TREATMENT COMPARISON META-ANALYSIS: A SIMULATION STUDY
Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES: To investigate the stability of comparative treatment effects in mul-
tiple treatment comparison meta-analyses where one sparsely informed treat-
ment comparison (i.e., a ‘weak link’) constitute the only available evidence for
linking two separate clusters of treatments.METHODS:We simulatedMTC scenar-
ios where two clusters of well-informed treatment comparisons (i.e., each compar-
ison included a large number of trials and patients) were connected by only one
sparsely informed comparisons, and where the treatments in one cluster were
generally more effective than in the other cluster. As a control, we also simulated
scenarios where the two clusters were connected by one well-informed compari-
son. We varied the degree of heterogeneity and baseline event rates across simu-
lation scenarios. We estimated the probability that the treatments in the cluster of
less effective treatments appeared better than to the treatments of the other clus-
ter, as well as the probability that they appeared similar – either judged by their
associated treatment rankings or by their comparative 95% credible intervals.
RESULTS: Treatment rankings were dominated by spurious treatment effect esti-
mates, and depending on the scenario, yielded misleading inferences in 10-30% of
MTCs. The 95% credible intervals generally had close to nominal coverage. Thus,
the less effective treatments rarely appeared significantly better. Power, however,
was typically lower than 20% to detect the superiority of the better treatments.
CONCLUSIONS: ‘Weak links’ in MTCs can occur over time when, for example, drug
combinations or new classes of drugs are introduced. Although clusters of com-
parisons (e.g., comparisons amongst drugs belonging to the same class) may be
well-informed by several trials and randomized patients, the overall comparative
effectiveness between all considered treatments may hinge primarily on a few
‘weak links’. When this happens it is important to recognize the statistical limita-
tions demonstrated in our simulations.
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USING DISCRETE CHOICE EXPERIMENTS (DCE) TO ESTIMATE PREFERENCE-
BASED UTILITIES FOR DUPUYTREN’S CONTRACTURE (DC)
Gu NY1, Botteman M1, Gerber R2, Ji X1, Postema R3, Wan W1, Sianos G4, Anthony I4,
Cappelleri JC5, Szczypa P6, Van Hout B7
1Pharmerit International, Bethesda, MD, USA, 2Pfizer, Inc., New London, CT, USA, 3Pharmerit
International, Rotterdam, The Netherlands, 4Glasgow Royal Infirmary, Glasgow, UK, 5Pfizer, Inc.,
Groton, CT, USA, 6Pfizer, Inc., Surrey, UK, 7Pharmerit International, York, UK
OBJECTIVES: Descrete Choice (DC) is a proliferative connective tissue disorder in
which fingers bend towards the palm and cannot be fully extended. DC’s quality of
life impact varies according to number/severity of affected fingers. To overcome
this heterogeneity, DCE methods were used to estimate DC utilities.METHODS: A
sample of theUnited Kingdomgeneral populationwas invited, via Internet, to state
preferences for varying hypothetical DC hand severity, defined using a combina-
tion of contractures (0°, 45° or 90°) in 8 joints [proximal interphalangeal (PIP) and
metacarpophalangeal (MCP) joints of the index, middle, ring and little fingers].
Using an optimal DCE design, 56 DC hands were selected from the 6,561 (38)
possible profiles. Right-handed, left-handed, and ambidextrous respondents were
asked to compare 10 randomly selected profile pairs and to indicate which hand,
within each pair, was preferable. To facilitate consistent comparisons, anatomi-
cally precise digital hand drawings were used. To anchor preferences on a tradi-
tional 0-1 utility scale, participants indicated how having themost severe hand (all
joints bent 90°) would affect their EQ-5D-5L profile. Unaffected hands were as-
sumed to have a utility of 1.0. Conditional logistic models were used to estimate
indirect utility weights for the joints, and were subsequently rescaled to EQ-5D-5L.
RESULTS: A total of 1745 participants provided valid and complete responses. An-
choring utilities for the most severe dominant, non-dominant, and ambidextrous
hands were 0.4909, 0.5688 and 0.6343, respectively. For a dominant hand with 90°
contracture in MCP joints of the ring and little fingers, the estimated utility was
0.8848. If only the MCP joint of the ring finger was affected, the utility was 0.9477
and increased to 0.9738 if the contracture was 45° instead. CONCLUSIONS:DCmay
be associated with relatively large utility decrements. The model provides a con-
venient and useful tool to estimate any preference-based DC utilities for clinical
and economic appraisals.
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ADAPTATION AND VALIDATION OF AN INDIAN VERSION OF THE HEALTH
RELATED QUALITY OF LIFE SCALE (IND-HAQ) IN INDIAN PATIENTS WITH
RHEUMATOID ARTHRITIS
Khera K1, Nagappa AN1, Balakrishnan R2, Sharma S3
1Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India, 2University of Michigan,
MI, MI, USA, 3GuruNanak Dev University, Jalandhar, India
OBJECTIVES: To test the validity and reliability of a newly developed Rheumatoid
Arthritis (RA) quality of life instrument: the Indian Health-Related Quality of Life
Instrument (IND-HAQ).METHODS: A total of 60 rheumatoid arthritis (RA) patients
were asked to complete the IND-HAQ at 2 time points (4 weeks apart). Patients also
completed the Stanford Health Assessment Questionnaire (PROMIS-HAQ) at the
second time point. PROMIS-HAQ scores were used to assess the validity of the
IND-HAQ. Besides the HAQ, the other outcome measures constituting the ACR
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